335 terminated. 335 Phase 3, 55 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 335 | Terminated 335 |
| Phase 2 | 55 | Terminated 55 |
Follow Mental Disorders: new trials by email Literature Review of Mental Disorders trials Research Report on Mental Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| An Open-Label Study to Assess the Long-term Safety of AXS-05 in Subjects With Dementia of the Alzheimer's Type, ADVANCE-2 and ACCORD-2 Extension Study AXS-05 (dextromethorphan-bupropion) - Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease | Phase 3 | Terminated | Axsome Therapeutics, Inc. | 139 | 2024-11-21 | 2026-06-25 |
| A Study of Aticaprant Plus an Antidepressant to Prevent Return of Depression Symptoms in Participants With Major Depressive Disorder Who Experience a Loss of Interest and Pleasure Aticaprant, Placebo - Depressive Disorder, Major, Anhedonia | Phase 3 | Terminated | Janssen Research & Development, LLC | 47 | 2024-09-19 | 2026-06-08 |
| Efficacy, Safety & Pharmacokinetic (PK) Study of HLD200 in Children Aged 4-5 Years With ADHD HLD200 methylphenidate hydrochloride capsules, Placebo HLD200 capsules - Attention Deficit Hyperactivity Disorder | Phase 3 | Terminated | Ironshore Pharmaceuticals and Development, Inc | 26 | 2024-09-13 | 2025-11-06 |
| SAINT for MDD in an Inpatient Setting Follow-on Active SAINT Stimulation, Sham SAINT Stimulation - Major Depressive Disorder, Major Depressive Episode | Phase 2 / Phase 3 | Terminated | Magnus Medical | 2 | 2024-06-30 | 2025-03-24 |
| The Effects of SAINT® Neuromodulation System on Explicit and Implicit Suicidal Cognition Active SAINT Stimulation, Sham SAINT Stimulation - Major Depressive Disorder, Major Depressive Episode | Phase 2 / Phase 3 | Terminated | Magnus Medical | 2 | 2024-06-30 | 2025-03-24 |
| A Study of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy and Long-term Extension Treatment With Aticaprant Aticaprant, Placebo - Depressive Disorder, Major, Anhedonia | Phase 3 | Terminated | Janssen Research & Development, LLC | 101 | 2024-06-26 | 2026-02-17 |
| Long-term Extension of Phase 3 Study of ALZ- 801 in APOE4/4 Early AD Subjects Experimental: ALZ-801 - Early Alzheimer's Disease | Phase 3 | Terminated | Alzheon Inc. | 163 | 2024-04-02 | 2026-06-25 |
| Study to Evaluate NRCT-101SR in Pediatric Subjects With ADHD NRCT-101SR - Attention-Deficit/Hyperactivity Disorder (ADHD) | Phase 2 / Phase 3 | Terminated | Neurocentria, Inc. | 95 | 2024-01-25 | 2026-01-15 |
| Continuation Study for Latozinemab Latozinemab - Neurodegenerative Diseases | Phase 3 | Terminated | Alector Inc. | 17 | 2023-12-08 | 2026-01-21 |
| Study to Assess the Safety and Effectiveness of NMRA-335140-501 NMRA-335140 - Major Depressive Disorder | Phase 3 | Terminated | Neumora Therapeutics, Inc. | 904 | 2023-11-10 | 2026-09-14 |
| Amitriptyline for Repetitive Behaviors in Autism Spectrum Disorders amitriptyline - Autism Spectrum Disorder, Repetitive Compulsive Behavior | Phase 3 | Terminated | University of Missouri, Kansas City | 1 | 2023-11-01 | 2025-05-30 |
| Randomized, Double-Blind, Placebo-Controlled Trial of REL-1017 as Adjunctive Treatment for MDD REL-1017, Placebo - Major Depressive Disorder, Depression | Phase 3 | Terminated | Levomecor Inc. | 27 | 2023-08-17 | 2026-07-10 |
| AGItated Patients Management: intraNASAL Midazolam vs Intramuscular Loxapine Intranasal midazolam, Intramuscular loxapine - Emergence Delirium | Phase 3 | Terminated | Assistance Publique - Hôpitaux de Paris | 1 | 2023-04-09 | 2024-05-28 |
| Study to Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as an Adjunctive Treatment for Schizophrenia Valbenazine, Placebo - Schizophrenia | Phase 3 | Terminated | Neurocrine Biosciences | 8 | 2023-01-05 | 2024-11-12 |
| Cannabidiol for the Treatment of Pelvic Pain in Endometriosis (DREAMLAND) Cannabis Derivatives, Placebo, Hormonal Contraceptive Agents - Endometriosis, Pelvic Pain | Phase 2 / Phase 3 | Terminated | University of Sao Paulo | 50 | 2023-01-03 | 2025-04-02 |
| A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Huntington's Disease SAGE-718 - Huntington's Disease | Phase 3 | Terminated | Supernus Pharmaceuticals, Inc. | 153 | 2022-12-14 | 2025-12-17 |
| Dexmedetomidine in the Treatment of Agitation Associated With Dementia (TRANQUILITY III) BXCL501, Matching Placebo - Agitation, Dementia | Phase 3 | Terminated | BioXcel Therapeutics Inc | 13 | 2022-12-05 | 2026-10-01 |
| An Open-label Study to Assess the Long-term Safety, Tolerability, Effectiveness, and Durability of Effect of KarXT in Patients With DSM-5 Diagnosis of Schizophrenia Xanomeline and Trospium Chloride Capsules - Schizophrenia | Phase 3 | Terminated | Karuna Therapeutics, Inc., a Bristol Myers Squibb company | 4 | 2022-11-08 | 2024-06-12 |
| Open-label Extension for Phase 3 Clinical Trials of Simufilam Simufilam - Alzheimer Disease | Phase 3 | Terminated | Cassava Sciences, Inc. | 1081 | 2022-11-07 | 2025-05-23 |
| A Study of Aticaprant in Adult and Elderly Participants With Major Depressive Disorder (MDD) Aticaprant - Depressive Disorder, Major | Phase 3 | Terminated | Janssen Research & Development, LLC | 871 | 2022-09-22 | 2026-10-06 |
Showing 20 of 335. Sign in to see all of them.
Alzheimer Disease (65) · Schizophrenia (51) · Depressive Disorder, Major (37) · Depression (35) · Dementia (26) · Bipolar Disorder (21) · Cognitive Dysfunction (16) · Sleep Initiation and Maintenance Disorders (13) · Anxiety Disorders (12) · Attention Deficit Disorder with Hyperactivity (12) · Psychotic Disorders (12) · Stress Disorders, Post-Traumatic (11) · Delirium (10) · Opioid-Related Disorders (10) · Constipation (9)
Nervous System Diseases (118) · Neurocognitive Disorders (95) · Brain Diseases (82) · Central Nervous System Diseases (81) · Neurodegenerative Diseases (69) · Mood Disorders (65) · Tauopathies (60) · Schizophrenia Spectrum and Other Psychotic Disorders (58) · Behavior (57) · Pathological Conditions, Signs and Symptoms (56) · Signs and Symptoms (54) · Dementia (53) · Behavioral Symptoms (44) · Neurologic Manifestations (44)
Quetiapine Fumarate (15) · Aripiprazole (13) · Risperidone (10) · Escitalopram (9) · ziprasidone (9) · Lisdexamfetamine Dimesylate (7) · Olanzapine (7) · bifeprunox (7) · Haloperidol (6) · Memantine (6) · Paroxetine (6) · gantenerumab (6) · bapineuzumab (5) · latrepirdine (5) · ramelteon (5)
Otsuka Pharmaceutical Development & Commercialization, Inc. (13) · H. Lundbeck A/S (12) · Pfizer (12) · AstraZeneca (9) · Hoffmann-La Roche (9) · Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (8) · Biogen (6) · Janssen Research & Development, LLC (6) · Massachusetts General Hospital (6) · Shire (6) · Eli Lilly and Company (5) · Assistance Publique - Hôpitaux de Paris (4) · Boehringer Ingelheim (4) · Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (4) · Denovo Biopharma LLC (4)
United States (216) · Canada (82) · Germany (61) · Spain (61) · France (60) · United Kingdom (53) · Poland (52) · Australia (47) · Italy (45) · South Korea (36) · Belgium (34) · Japan (33) · Netherlands (32) · Sweden (32) · Russia (31)
Jenna Hoogerheyde (4) · Brandon Bentzley, MD (2)
PMID 40603145, PMID 39556389, PMID 41537338, PMID 42841310, PMID 21889833, PMID 24111983, PMID 26297092, PMID 27176461, PMID 27334799, PMID 27767991, PMID 27807285, PMID 31390660, PMID 31764959, PMID 32840872, PMID 33049114, PMID 34807243, PMID 35384522, PMID 35394365, PMID 35747889, PMID 36121669, PMID 36600109, PMID 36641609, PMID 37966285, PMID 38165296, PMID 39498781, PMID 39816573, PMID 39887500, PMID 40302041, PMID 42598748, PMID 14702256, PMID 17474812, PMID 18041437, PMID 18378947, PMID 18447935, PMID 18671864, PMID 20707781, PMID 20798023, PMID 20861739, PMID 21186964, PMID 21199966, PMID 21486110, PMID 21518701, PMID 21653649, PMID 21852093, PMID 23057791, PMID 23265409, PMID 23472619, PMID 23898805, PMID 23926422, PMID 24086352
2016 (9), 2015 (7), 2017 (6), 2023 (4), 2008 (3), 2009 (3), 2019 (3), 2005 (2), 2018 (2), 1UF1AG046150-01 (1), 2014 (1), K23HL078760 (1), R01AG046179 (1), R01AG053267 (1), R01MH125160 (1)